National Comprehensive Cancer Network

National Comprehensive Cancer Network National Comprehensive Cancer Network is a not-for-profit alliance of 34 leading cancer centers.

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of leading cancer centers is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives

The NCCN Member Institutions are:
Abramson Cancer Center at the University of Pennsylvania
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
City of Hope National Medical Center
Dana-Farber/Brigham and Women’s Cancer Center | Mass General Cancer Center
Duke Cancer Institute
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Fred Hutchinson Cancer Center
Huntsman Cancer Institute at the University of Utah
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Hopkins Kimmel Cancer Center
Mayo Clinic Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center
O'Neal Comprehensive Cancer Center at UAB
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Roswell Park Comprehensive Cancer Center
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
Stanford Cancer Institute
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
The UChicago Medicine Comprehensive Cancer Center
The University of Texas MD Anderson Cancer Center
UC Davis Comprehensive Cancer Center
UC San Diego Moores Cancer Center
UCLA Jonsson Comprehensive Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
University of Colorado Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
UT Southwestern Simmons Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Yale Cancer Center/Smilow Cancer Hospital

Welcome to the second and final day of the NCCN 2026 Annual Congress: Hematologic Malignancies™!  Morning sessions will ...
09/19/2026

Welcome to the second and final day of the NCCN 2026 Annual Congress: Hematologic Malignancies™! Morning sessions will begin with topics focusing on outpatient administration of bispecific antibodies and CAR T-Cell Therapies and how to manage toxicities.
You can still register to attend virtually: https://bit.ly/Hem2026

Sessions at the Hematologic Malignancies Congress highlighted topics, including clonal hematopoiesis in hematologic mali...
09/18/2026

Sessions at the Hematologic Malignancies Congress highlighted topics, including clonal hematopoiesis in hematologic malignancies and evolving treatment strategies in multiple myeloma.
Tune in for more sessions tomorrow: https://bit.ly/Hem2026

Stop by NCCN Exhibit  #52 &  #54 today to pick up FREE NCCN Guidelines for Patients, demo NCCN products, learn about NCC...
09/18/2026

Stop by NCCN Exhibit #52 & #54 today to pick up FREE NCCN Guidelines for Patients, demo NCCN products, learn about NCCN resources and programs, connect with staff members, enjoy giveaways, and more! https://bit.ly/Hem2026

Welcome to the NCCN 2026 Annual Congress: Hematologic Malignancies™! The afternoon begins with sessions focused on AML, ...
09/18/2026

Welcome to the NCCN 2026 Annual Congress: Hematologic Malignancies™! The afternoon begins with sessions focused on AML, including how to transform management and oral targeted therapies for relapsed/refractory disease.
You can still register to join virtually: https://bit.ly/Hem2026

Thank you to all of the experts who have been participating in NCCN Guidelines Panel meetings this year: We appreciate y...
09/16/2026

Thank you to all of the experts who have been participating in NCCN Guidelines Panel meetings this year: We appreciate your time, expertise, and continued commitment to advancing cancer care!

Join us October 16 or an Optimizing Patient Outcomes webinar focusing on Management of Bispecific T-Cell Engager Toxicit...
09/15/2026

Join us October 16 or an Optimizing Patient Outcomes webinar focusing on Management of Bispecific T-Cell Engager Toxicities: How to Balance Increased Efficacy with Notable Toxicity. Our presenters from Penn Medicine will outline implementation of an interprofessional standard operating procedure for evaluating product-specific site of care administration and managing bispecific antibody toxicity in clinic and at home.
Register now: https://education.nccn.org/node/98730

The NCCN 2026 Annual Congress: Hematologic Malignancies™ is almost here! Join us September 18–19 in NYC or virtually for...
09/09/2026

The NCCN 2026 Annual Congress: Hematologic Malignancies™ is almost here! Join us September 18–19 in NYC or virtually for two days of expert-led education and engaging discussions on hematologic malignancies.
Don’t miss out, register today: https://bit.ly/Hem2026

Address

3025 Chemical Road, Suite 100
Plymouth Meeting, PA
19462

Alerts

Be the first to know and let us send you an email when National Comprehensive Cancer Network posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to National Comprehensive Cancer Network:

Shortcuts

Share